Botulism Immune Globulin Intravenous (Human) – BabyBIG®

Revision Date: May 27, 2013

Please consult the Product Prescribing Information¹ for further information about this product.

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Distributed for Infant Botulism Treatment and Prevention Program, California Department of Public Health</th>
</tr>
</thead>
</table>
| Authorization and access | Special authorization and access procedures must be followed:
1. The Office of the Chief Medical Officer of Health (OCMOH) must be notified by the fastest means possible of all cases in which botulism antitoxin is required.
2. Available on a 24-hour basis from Alberta Health by calling the OCMOH pager: 780-638-3630. A Special Access Program (SAP) Form is included with the product and must be completed and returned to Alberta Health.

Note: This product is not stocked in the Provincial Vaccine Depot. |

| Indications for use of botulism immune globulin | Treatment of infant botulism caused by toxin types A or B
3. Administer as soon as clinical diagnosis of infant botulism is made.
4. Use for infants younger than one year of age.

For further information about the disease and reporting requirements refer to the Public Health Notifiable Disease Management Guidelines – Botulism.² |

| Dose | 1.5 mL/kg (75mg/kg)¹ BabyBig is supplied in single-use vials of 100mg ±20mg lyophilized immunoglobulin. Reconstitution as directed on the Product Information results in a BabyBig solution concentration of 50mg/mL

Refer to: Product Prescribing Information¹

Note: This is a treatment product administered under the direction of a physician in an acute care setting. |

| Route | Intravenous infusion

Refer to: Product Prescribing Information¹ |

| Schedule | • Initiate infusion within two hours of reconstitution through a separate IV line. Begin infusion slowly (0.5mL/kg/h); if no untoward reaction within 15 minutes, increase rate to 1.0mL/kg/h. |

References
